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Other names: BHD; FLCL; Folliculin 
Location: 17p11.2 
Note: Putative tumor suppressor gene. 
DNA/RNA 
Description 
The FLCN/BHD gene consists of a 3717 nt mRNA 
(using NM_144997 derived from BQ423946 and 
AF517523, the coding sequence extends from nt499 to 
nt2238) and contains 14 coding exons. The initiation 
codon is located within exon 4. 
Transcription 
Northern blot analysis revealed a 3.8 kb FLCN/BHD 
mRNA transcript expressed in most tissues  
Alternate splicing of FLCN/BHD results in two 
transcript variants encoding two different isoforms. 
Transcript 1 is the full-length isoform. Transcript 2 has 




The BHD protein, folliculin (FLCN), consists of 579 
amino acids with a central glutamic acid-rich coiled-
coil domain, one N-glycosylation site and three 
myristoylation sites, and an estimated molecular weight 
of 64.5 kDa. 
Expression 
Expressed in most major adult tissues, including 
kidney, lung and skin, which are involved in the BHD 
phenotype. 
Localisation 
Epitope-tagged FLCN expressed in HEK293 cells 
localized in both the nucleus and cytoplasm by 
fluorescence in situ hybridization. 
Function 
FLCN is a novel protein, with no characteristic 
domains to suggest function. Coimmunoprecipitation 
studies have identified a novel folliculin-binding 
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activated protein kinase (AMPK), a key molecule for
energy sensing and a negative regulator of mTOR 
(mammalian target of rapamycin). FLCN exists in 
signaling including rapamycin and amino acid 
starvation, and by an AMPK inhibitor, Compound C. 
These data suggest that FLCN and its interacting 
partner, FNIP1, may be involved in energy and 
nutrient-sensing through the AMPK and mTOR 
signaling pathways. 
Using a genetic approach in Drosophila, RNA 
interference studies to decrease expression of the fly 
BHD homolog, DBHD, have established a requirement 
for DBHD in male germline stem cell maintenance in 
the fly testis. Further genetic studies to examine th  
interaction between DBHD and the JAK/STAT 
pathway, which is necessary for germline stem cell 
self-renewal, suggested that DBHD may regulate 
maintenance of germline stem cells downstream of or 
in parallel with the JAK/STAT and Dpp (a TGFbeta 
family member) signaling pathways. Thus the work 
with the Drosophila homolog of FLCN/BHD supports a 
potential role for DBHD in stem cell maintenance and 
raises the possibility that dysregulation of FLCN in 
human tumors may result from aberrant modulation of 
stem cells. 
Homology 
Folliculin shows no strong homology to any known 
proteins but is evolutionarily conserved, and orthologs 
have been identified in chimpanzee, dog, cow, rat, 
mouse, red jungle fowl, frog, fly, and worm. 
Mutations 
Germinal 
All FLCN/BHD germline mutations identified in Birt-
Hogg-Dubé (BHD) patients are predicted to truncate 
the mutant protein, including frameshift 
(insertions/deletions), nonsense and splice-site 
mutations. To date, no missense germline mutations 
have been identified. The mutation detection rate in 
BHD families is about 84%. Mutations are located 
along the entire length of the coding region, with no 
genotype-phenotype correlations noted between type of 
mutation, location within the gene and phenotypic 
disease manifestations (BHD skin lesions, lung 
cysts/spontaneous pneumothorax and renal tumors). 
The most frequent mutation found in the germline of 
BHD patients is the insertion or deletion of a cytosine 
in a C8 tract located in exon 11, predicted to cause a 
frameshift and prematurely truncate the mutant protein. 
This hot spot mutation occurs in about half of all BHD 
patients. Among BHD patients with the exon 11 
mutation, significantly fewer renal tumors developed in 
patients with the C-deletion than those with the C-
insertion mutation. 
Germline FLCN/BHD mutations have been reported in 
primary spontaneous pneumothorax (PSP) families 
with nearly 100% penetrance in family members in 
which lung blebs or bullae indicated affected status. 
The PSP-associated mutations, including 2 nonsense 
and one 4-bp deletion, are predicted to prematurely 
truncate the protein and are located in exons 9, 12 and 
4, respectively. 
Somatic 
FLCN/BHD somatic mutations have been found at only 
a very low frequency (0-10%) in sporadic renal tumors 
and therefore, may not represent a major mechanism 
for the development of sporadic renal carcinoma. Loss 
of 17p DNA including p53 (36%) or partial 
methylation (28%) of the FLCN/BHD promoter were 
reported in sporadic renal carcinomas with various 
histologies. 
Mutations have been identified in the mutational hot
spot in exon 11 of the FLCN/BHD gene in other tumor 
types exhibiting microsatellite instability, including 
colorectal carcinoma (20%), endometrial carcinoma 
(12%) and gastric carcinoma (16%). 
Implicated in 
Birt-Hogg-Dubé (BHD) syndrome 
Disease 
Birt-Hogg-Dubé (BHD) syndrome is an inherited 
autosomal dominant genodermatosis characterized by 
benign tumors of the hair follicle (fibrofolliculoma), 
lung cysts, spontaneous pneumothorax and renal 
neoplasia. Colon polyps or colon cancer may be part of 
the disease manifestations in some BHD cohorts 
although no statistically significant association was 
found. BHD syndrome is caused by germline mutations 
in the FLCN/BHD gene. Any or all of these phenotypic 
features may develop in a BHD patient; the phenotype 
is variable within and among BHD families inheriting 
the identical FLCN/BHD mutation (i.e., C-
insertion/deletion in exon 11). 
Prognosis 
BHD is a rare disorder occurring in about 1/200,000 
individuals. The BHD skin lesions, which develop after 
puberty (above 25 years of age) are highly penetrant 
(above 85%) and may be disfiguring, but they are 
benign and have no health consequences. Lung cysts 
detected by thoracic CT scan are very frequent (above 
85%) in BHD patients. Episodes of spontaneous 
pneumothorax in BHD patients occur with a higher 
frequency before the age of 40, and repeat episodes 
cease after surgical intervention. The risk for 
developing renal neoplasia is about 7-fold higher for 
BHD mutation carriers than for their unaffected 
siblings. Most commonly, chromophobe renal 
carcinoma (34%) and oncocytic hybrid tumors (50%), 
develop in about half of BHD families with an average 
age at diagnosis of 48-50 and a male/female ratio of 
2:1. Tumors may develop bilaterally with multiple foci 
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or unilaterally with a single focus, and variable tumor 
histology may be seen in a single patient’s kidney and
among BHD family members carrying the same 
FLCN/BHD mutation. 
Oncogenesis 
Patients with BHD syndrome are at a higher risk for the 
development of chromophobe renal carcinoma, 
oncocytic hybrid renal tumors and clear cell renal 
carcinoma, which may be aggressive and metastatic. 
Renal oncocytosis, which are small clusters of cells 
resembling those found in the larger hybrid tumors, 
have been found scattered throughout the kidney of a
majority of BHD patients, suggesting that the entire 
renal parenchyma may be at risk for tumor 
development. Second hit somatic mutations in the 
remaining wild type copy of the FLCN/BHD gene have 
been identified in renal tumors from BHD patients with 
germline mutations and may contribute to the 
progression of renal oncocytosis to renal neoplasia (see 
below). 
Primary Spontaneous Pneumothorax 
(PSP) 
Disease 
Primary spontaneous pneumothorax is a condition in 
which air is present in the pleural space without a 
precipitating event that results in the secondary partial 
or complete collapse of the lung. FLCN/BHD 
mutations have been found associated with inherited 
autosomal dominant primary spontaneous 
pneumothorax (PSP) in some PSP families. In these 
families PSP was the only phenotypic feature and the 
mutation was 100% penetrant with lung bullae. 
To be noted 
Note: Animal models of BHD: A germline single 
nucleotide insertion in the first coding exon of the rat 
Bhd ortholog was found in the Nihon rat, an established 
animal model of renal carcinoma, which develops renal 
tumors by 8 weeks of age. A germline mutation in the 
canine Bhd ortholog, which changes a conserved 
histidine to arginine (H255R), gives rise to RCND 
(renal cystadenoma nodular dermatofibroma) in the 
German Shepherd dog with a renal tumor and skin 
nodule phenotype. 
Tumor suppressor role for FLCN/BHD: Somatic 
mutations in the wild type copy of the FLCN/BHD 
gene or loss of heterozygosity at 17p11.2 have been 
identified in a majority of renal tumors from BHD 
patients who inherit germline mutations, suggesting 
that FLCN/BHD may act as a tumor suppressor gene. 
Tumors from a single BHD patient have different 
second mutations or LOH, but within the same tumor, 
even within regions with different histologies, the same  
second mutation was observed, suggesting that multiple 
tumors arise from independent, clonal events initiated 
by the second hit. 
Haploinsufficiency, however, may be sufficient for the 
development of the benign hair follicle tumors 
(fibrofolliculomas), because the wild type copy of the 
FLCN/BHD gene is retained in microdissected tissue 
from these skin lesions. 
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